FDA grants orphan drug designation to BIV201 for treatment of Acsites
Release Date: 11-Oct-2016
BioVie Inc., a company dedicated to discovering and developing therapeutic drugs, declares that it’s new drug candidate BIV201 has received orphan drug designation for the treatment of acsites due to chronic liver cirrhosis.
Currently, BioVie is looking forward to complete an investigational new drug (IND) application for BIV201 having potent vasoconstrictor as an active ingredient, which qualifies the drug for effective treatment of various life threatening diseases including type 1 hepatorenal syndrome (HRS), esophageal variceal bleeds, and sepsis.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.